1. Home
  2. MLYS vs SMBK Comparison

MLYS vs SMBK Comparison

Compare MLYS & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • SMBK
  • Stock Information
  • Founded
  • MLYS 2019
  • SMBK N/A
  • Country
  • MLYS United States
  • SMBK United States
  • Employees
  • MLYS N/A
  • SMBK N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • SMBK Major Banks
  • Sector
  • MLYS Health Care
  • SMBK Finance
  • Exchange
  • MLYS Nasdaq
  • SMBK Nasdaq
  • Market Cap
  • MLYS 526.1M
  • SMBK 534.5M
  • IPO Year
  • MLYS 2023
  • SMBK N/A
  • Fundamental
  • Price
  • MLYS $10.21
  • SMBK $35.32
  • Analyst Decision
  • MLYS Strong Buy
  • SMBK Buy
  • Analyst Count
  • MLYS 2
  • SMBK 6
  • Target Price
  • MLYS $30.00
  • SMBK $30.50
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • SMBK 55.9K
  • Earning Date
  • MLYS 03-20-2025
  • SMBK 01-21-2025
  • Dividend Yield
  • MLYS N/A
  • SMBK 0.91%
  • EPS Growth
  • MLYS N/A
  • SMBK 26.63
  • EPS
  • MLYS N/A
  • SMBK 2.14
  • Revenue
  • MLYS N/A
  • SMBK $166,349,000.00
  • Revenue This Year
  • MLYS N/A
  • SMBK N/A
  • Revenue Next Year
  • MLYS N/A
  • SMBK $9.70
  • P/E Ratio
  • MLYS N/A
  • SMBK $16.24
  • Revenue Growth
  • MLYS N/A
  • SMBK 11.36
  • 52 Week Low
  • MLYS $8.58
  • SMBK $19.00
  • 52 Week High
  • MLYS $16.91
  • SMBK $37.72
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 44.53
  • SMBK 61.57
  • Support Level
  • MLYS $9.57
  • SMBK $34.88
  • Resistance Level
  • MLYS $10.79
  • SMBK $35.87
  • Average True Range (ATR)
  • MLYS 0.64
  • SMBK 0.86
  • MACD
  • MLYS 0.11
  • SMBK 0.36
  • Stochastic Oscillator
  • MLYS 63.98
  • SMBK 77.62

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

Share on Social Networks: